High-grade endometrial carcinomas - strategies for typing

Histopathology

Volumn 62, Issue 1, 2013, Pages 89-110

  Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Carcinosarcoma; Genotype; Immunohistochemistry; MMMT; Morphologically ambiguous; Undifferentiated carcinoma; Uterine clear cell carcinoma; Uterine serous carcinoma

Indexed keywords

ALGORITHM; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CARCINOSARCOMA; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; GENOTYPE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH GRADE ENDOMETRIUM CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVIEW;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, ENDOMETRIOID; CARCINOSARCOMA; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; NEOPLASM GRADING; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871146770     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12029     Document Type: Review

References (101)

1. Gilks CB, Oliva E, Soslow R. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Lab. Invest. 2011; 91; 248A.
2. Boruta DM, Gehrig PA, Groben PA et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004; 10; 2214-2221.
3. Cirisano FD Jr, Robboy SJ, Dodge RK et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol. Oncol. 1999; 74; 385-394.
4. Cirisano FD Jr, Robboy SJ, Dodge RK et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol. Oncol. 2000; 77; 55-65.
5. Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol. Oncol. 2004; 95; 593-596.
6. Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study. Eur. J. Gynaecol. Oncol. 2002; 23; 300-304.
7. Hamilton CA, Cheung MK, Osann K et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer 2006; 94; 642-646.
8. Soslow RA, Bissonnette JP, Wilton A et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am. J. Surg. Pathol. 2007; 31; 979-987.
9. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am. J. Surg. Pathol. 2007; 31; 1653-1661.
10. Silverberg SG, Major FJ, Blessing JA et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int. J. Gynecol. Pathol. 1990; 9; 1-19.
11. Nofech-Mozes S, Ghorab Z, Ismiil N et al. Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases. Am. J. Clin. Pathol. 2008; 129; 110-114.
12. Rasool N, Fader AN, Seamon L et al. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol. Oncol. 2010; 116; 10-14.
13. van Wijk FH, van der Burg ME, Burger CW, Vergote I, van Doorn HC. Management of recurrent endometrioid endometrial carcinoma: an overview. Int. J. Gynecol. Cancer 2009; 19; 314-320.
14. Mariani A, Webb MJ, Keeney GL, Lesnick TG, Podratz KC. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol. Oncol. 2002; 87; 274-280.
15. Alektiar KM, McKee A, Lin O et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int. J. Radiat. Oncol. Biol. Phys. 2002; 54; 79-85.
16. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 1982; 6; 93-108.
17. Aquino-Parsons C, Lim P, Wong F, Mildenberger M. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. Gynecol. Oncol. 1998; 71; 83-86.
18. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int. J. Gynecol. Pathol. 1995; 14; 30-38.
19. Malpica A, Tornos C, Burke TW, Silva EG. Low-stage clear-cell carcinoma of the endometrium. Am. J. Surg. Pathol. 1995; 19; 769-774.
20. Catasus L, D'Angelo E, Pons C, Espinosa I, Prat J. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod. Pathol. 2010; 23; 694-702.
21. Catasus L, Gallardo A, Cuatrecasas M, Prat J. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod. Pathol. 2009; 22; 522-529.
22. An HJ, Logani S, Isacson C, Ellenson LH. Molecular characterization of uterine clear cell carcinoma. Mod. Pathol. 2004; 17; 530-537.
23. Hayes MP, Wang H, Espinal-Witter R et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin. Cancer Res. 2006; 12; 5932-5935.
24. McConechy MK, Ding J, Cheang MC et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J. Pathol. 2012; 228; 20-30.
25. Wiegand KC, Lee AF, Al-Agha OM et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol. 2011; 224; 328-333.
26. Guan B, Mao TL, Panuganti PK et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am. J. Surg. Pathol. 2011; 35; 625-632.
27. Tashiro H, Blazes MS, Wu R et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997; 57; 3935-3940.
28. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma - evidence of distinct molecular genetic pathways. Cancer 2000; 88; 814-824.
29. Black D, Soslow RA, Levine DA et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J. Clin. Oncol. 2006; 24; 1745-1753.
30. Goodfellow PJ, Buttin BM, Herzog TJ et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc. Natl Acad. Sci. USA. 2003; 100; 5908-5913.
31. Soslow RA, Shen PU, Chung MH, Isacson C. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int. J. Gynecol. Pathol. 1998; 17; 129-134.
32. Ambros RA, Sheehan CE, Kallakury BV et al. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod. Pathol. 1996; 9; 1165-1169.
33. Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur. J. Gynaecol. Oncol. 2001; 22; 122-126.
34. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod. Pathol. 2006; 19; 1091-1100.
35. Alvarez T, Miller E, Duska L, Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am. J. Surg. Pathol. 2012; 36; 753-761.
36. Kuhn E, Kurman RJ, Vang R et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma - evidence supporting the clonal relationship of the two lesions. J. Pathol. 2012; 226; 421-426.
37. Kobel M, Reuss A, Bois A et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J. Pathol. 2010; 222; 191-198.
38. Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int. J. Gynecol. Pathol. 2012; 31; 48-56.
39. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 1997; 150; 177-185.
40. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol. Oncol. 2009; 113; 370-373.
41. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int. J. Gynecol. Pathol. 2007; 26; 328-333.
42. Egan JA, Ionescu MC, Eapen E, Jones JG, Marshall DS. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int. J. Gynecol. Pathol. 2004; 23; 119-122.
43. Yemelyanova A, Ji H, Shih IeM, Wang TL, Wu LS, Ronnett BM. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am. J. Surg. Pathol. 2009; 33; 1504-1514.
44. Alkushi A, Clarke BA, Akbari M et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod. Pathol. 2007; 20; 1156-1165.
45. Nofech-Mozes S, Khalifa MA, Ismiil N et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod. Pathol. 2008; 21; 1147-1155.
46. Broaddus RR, Lynch HT, Chen LM et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006; 106; 87-94.
47. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum. Pathol. 1998; 29; 551-558.
48. Arai T, Watanabe J, Kawaguchi M et al. Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int. J. Gynecol. Cancer 2006; 16; 391-395.
49. Soslow RA. Endometrial carcinomas with ambiguous features. Semin. Diagn. Pathol. 2010; 27; 261-273.
50. Alkushi A, Köbel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int. J. Gynecol. Pathol. 2010; 29; 343-350.
51. Darvishian F, Hummer AJ, Thaler HT et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am. J. Surg. Pathol. 2004; 28; 1568-1578.
52. DeLair D, Soslow R, Gilks B, Macias A, Oliva E. The morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 83 cases. Mod. Pathol. 2009; 22(Suppl. 1); 211A (abstract 961).
53. Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 2003; 163; 2503-2512.
54. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod. Pathol. 2006; 19; 83-89.
55. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum. Pathol. 2007; 38; 1074-1080.
56. Kobel M, Kalloger SE, Carrick J et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am. J. Surg. Pathol. 2009; 33; 14-21.
57. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl. Immunohistochem. Mol. Morphol. 2012; 20; 580-587.
58. DeLair D, Soslow RA. Endometrial clear cell carcinomas with and without aberrant p53 expression: a study of 16 cases. Lab. Invest. 2012; 92; 265A-266A.
59. Soslow RA, Longacre TA. Uterine pathology. In Weiss L ed. Illustrated surgical pathology. New York, NY: Cambridge University Press, 2012; 127-160.
60. Oliva E, Soslow RA. High-grade endometrial carcinomas. Surg. Pathol. Clin. 2011; 4; 199-242.
61. Garg K, Leitao MM Jr, Wynveen CA et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod. Pathol. 2010; 23; 80-92.
62. Soslow RA, Wethington SL, Cesari M et al. Clinicopathological analysis of matched primary and recurrent endometrial carcinoma. Am. J. Surg. Pathol. 2012; 36; 1771-1781.
63. Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG. Undifferentiated carcinoma of the endometrium. Am. J. Surg. Pathol. 2005; 29; 1316-1321.
64. Silva EG, Deavers MT, Bodurka DC, Malpica A. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int. J. Gynecol. Pathol. 2006; 25; 52-58.
65. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod. Pathol. 2010; 23; 781-789.
66. Al-Agha OM, Garg K, Tafe LJ, Huntsman D, Soslow RA. Loss of E-cadherin is a shared feature of both sarcomatous and undifferentiated components of uterine carcinosarcomas and dedifferentiated carcinomas. Lab. Invest. 2010; 90; 233A.
67. Murray SK, Clement PB, Young RH. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am. J. Surg. Pathol. 2005; 29; 157-166.
68. Silva EG, Young RH. Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am. J. Surg. Pathol. 2007; 31; 1203-1208.
69. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am. J. Surg. Pathol. 1992; 16; 600-610.
70. Quddus MR, Sung CJ, Zhang C, Lawrence WD. Minor serous and clear cell components adversely affect 'prognosis in 'mixed-type' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod. Sci. 2010; 17; 673-678.
71. Alkushi A, Abdul-Rahman ZH, Lim P et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am. J. Surg. Pathol. 2005; 29; 295-304.
72. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am. J. Surg. Pathol. 2000; 24; 1201-1208.
73. Garg K, Kauff N, Soslow RA. Endometrial carcinomas with DNA mismatch repair abnormalities: genotypic phenotypic correlations. Mod. Pathol. 2011; 24(Suppl. 1); 247A (abstract 1045).
74. Garg K, Leitao MM Jr, Kauff ND et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am. J. Surg. Pathol. 2009; 33; 925-933.
75. Garg K, Soslow RA. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J. Clin. Pathol. 2009; 62; 679-684.
76. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983; 15; 10-17.
77. Setiawan V, Yang HP, Pike MC et al. The association of body mass index with risk of endometrial cancer subtypes: pooled analysis in E2C2. In Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 2012: Chicago, IL. Cancer Res.. 2012; 72(Suppl. 1); Abstract 1029.
78. Ueda SM, Kapp DS, Cheung MK et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am. J. Obstet. Gynecol. 2008; 198; 218e1-218e6.
79. Wright JD, Fiorelli J, Schiff PB et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 2009; 115; 1276-1285.
80. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am. J. Clin. Pathol. 1990; 94; 247-254.
81. Soslow RA, Shen PU, Chung MH, Isacson C, Baergen RN. Cyclin D1 expression in high-grade endometrial carcinomas - association with histologic subtype. Int. J. Gynecol. Pathol. 2000; 19; 329-334.
82. N.C.I. Surveillance Research Program. 2012. Fast Stats: An interactive tool for access to SEER cancer statistics. Available at: http://seer.cancer.gov. Accessed 10 September 2012.
83. Shia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum. Pathol. 2008; 39; 116-125.
84. Lu KH, Schorge JO, Rodabaugh KJ et al. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J. Clin. Oncol. 2007; 25; 5158-5164.
85. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J. Mol. Diagn. 2008; 10; 293-300.
86. Hampel H, Frankel W, Panescu J et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006; 66; 7810-7817.
87. De Leeuw WJF, Dierssen J, Vasen HF et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J. Pathol. 2000; 192; 328-335.
88. Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am. J. Surg. Pathol. 2007; 31; 744-751.
89. Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am. J. Surg. Pathol. 2009; 33; 1869-1877.
90. Resnick K, Straughn JM Jr, Backes F, Hampel H, Matthews KS, Cohn DE. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet. Gynecol. 2009; 114; 530-536.
91. Resnick KE, Hampel H, Fishel R, Cohn DE. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol. Oncol. 2009; 114; 128-134.
92. Carcangiu ML, Radice P, Casalini P, Bertario L, Merola M, Sala P. Lynch syndrome-related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types. Int. J. Surg. Pathol. 2010; 18; 21-26.
93. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995; 108; 1405-1411.
94. Lancaster JM, Powell CB, Kauff ND et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol. Oncol. 2007; 107; 159-162.
95. Westin SN, Lacour RA, Urbauer DL et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J. Clin. Oncol. 2008; 26; 5965-5971.
96. Soliman PT, Broaddus RR, Schmeler KM et al. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J. Clin. Oncol. 2005; 23; 9344-9350.
97. Baergen RN, Warren CD, Isacson C, Ellenson LH. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int. J. Gynecol. Pathol. 2001; 20; 214-219.
98. Euscher ED, Malpica A, Deavers MT, Silva EG. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am. J. Surg. Pathol. 2005; 29; 1074-1078.
99. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am. J. Clin. Pathol. 2002; 117; 541-545.
100. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int. J. Gynecol. Pathol. 2004; 23; 110-118.
101. Dupont J, Wang X, Marshall DS et al. Wilms tumor gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol. Oncol. 2004; 94; 449-455.